Klinische Forschung Hannover-Mitte GmbH

The research at Klinische Forschung Hannover-Mitte GmbH focuses on innovative strategies to reduce the risk of heart attacks, strokes, and related events in patients with atherosclerotic cardiovascular disease and atrial fibrillation.

• Evaluation of novel anticoagulant‑free therapies for high‑risk atrial fibrillation
• Lipoprotein(a) lowering agents aimed at decreasing major cardiovascular events
• Combination treatments targeting heart failure with reduced ejection fraction

With 28 active trials and a team of 12 investigators, the site is a hub for cardiovascular innovation.

Studies are exploring symptom relief and gut health improvement for conditions such as irritable bowel syndrome and functional diarrhea.

• Probiotic therapy to normalize bowel movements in IBS‑D patients
• Assessment of quality‑of‑life outcomes following dietary interventions
• Safety profiling of novel microbiome‑modulating agents

The program highlights the site’s commitment to advancing digestive health research.

Research includes treatments for hormone‑related hair loss and menopausal symptoms that affect women’s well‑being.

• Oral minoxidil combined with topical therapy for androgenetic alopecia in women
• Evaluation of non‑hormonal options for vasomotor symptoms during breast cancer therapy
• Patient‑reported outcomes measuring quality of life improvements

The site’s multidisciplinary approach supports women’s health across the lifespan.

Investigations target endocrine imbalances that contribute to metabolic and reproductive disorders, including elevated Lp(a) and insulin‑related conditions.

• Lipid‑lowering therapies to achieve individualized LDL‑C targets
• Combination regimens addressing both cholesterol and Lp(a) levels
• Monitoring of hormonal biomarkers for safety and efficacy

These trials reflect the site’s expertise in precision medicine for hormonal regulation.

The portfolio includes immunomodulatory agents aimed at reducing inflammation in autoimmune conditions such as rheumatoid arthritis and polymyalgia rheumatica.

• Biologic therapies assessing joint inflammation and function
• Steroid‑sparing strategies for long‑term disease control
• Patient‑centered endpoints evaluating pain and mobility

Immunology research at the site benefits from close collaboration with rheumatology specialists.

Ongoing work evaluates pain‑relief options for chronic low back pain and osteoarthritis, aiming to improve mobility without reliance on opioids.

• Dose‑response studies of novel analgesics for non‑specific low back pain
• Oral agents targeting joint discomfort in knee osteoarthritis
• Functional assessments using standardized pain questionnaires

The site’s trials address a major source of disability in the aging population.

Research explores treatments for neurological complications, including cognitive deficits after viral infections and migraine prevention.

• Ginkgo biloba extract for post‑COVID‑19 cognitive impairment
• CGRP antagonist therapy to reduce migraine frequency
• Objective cognitive testing to measure treatment impact

These studies contribute to better management of both acute and chronic neurological conditions.

Trials focus on metabolic risk factors such as elevated cholesterol, hypertension, and obesity‑related joint pain.

• Novel antihypertensive agents evaluated for systolic blood pressure reduction
• Combination therapy with SGLT2 inhibitors for heart failure patients
• Weight‑loss interventions assessing pain outcomes in knee osteoarthritis

The multidisciplinary team integrates cardiometabolic expertise to tackle complex disease profiles.

The site conducts studies on chronic lung conditions, including chronic obstructive pulmonary disease and emerging viral infections.

• Anti‑inflammatory biologics to reduce COPD exacerbations
• Vaccine candidates targeting influenza and respiratory syncytial virus
• Novel cough suppressants for refractory chronic cough

Respiratory research benefits from advanced pulmonary function testing facilities.

Investigations address dermatologic and connective‑tissue disorders, aiming to improve skin health and reduce systemic inflammation.

• Topical and systemic therapies for hormone‑related alopecia
• Evaluation of anti‑inflammatory agents in connective tissue disease flares
• Patient‑reported outcomes on skin appearance and comfort

Dermatology collaborations enhance the depth of these therapeutic explorations.

Clinical work includes vaccine development and antiviral strategies against influenza, RSV, and human metapneumovirus.

• mRNA vaccine safety and efficacy compared with licensed influenza vaccine
• Recombinant virus‑like particle vaccines for RSV and hMPV in older adults
• Immunogenicity assessments following seasonal revaccination

The site’s virology unit supports rapid evaluation of emerging infectious disease threats.

Studies aim to improve mental health outcomes by testing non‑pharmacologic and pharmacologic interventions for insomnia, depression, and post‑COVID cognitive issues.

• Novel hypnotic agents for insomnia disorder
• Herbal formulations evaluated for mild to moderate major depressive disorder
• Cognitive enhancers targeting post‑viral brain fog

Psychological assessments are integrated to capture changes in mood, sleep, and cognition.